CASTLEFORD, England, September 7, 2011 /PRNewswire/ --
We are pleased to announce the launch of generic levetiracetam film-coated tablets.
Levetiracetam is a generic version of Keppra® (levetiracetam) from UCB Pharma Limited and is indicated as a monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
It is also indicated as adjunctive therapy:
- in the treatment of partial onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Levetiracetam from Teva UK Limited is available immediately in four strengths as 250, 500, 750 and 1,000mg film-coated tablets, in packs of 60.
The Teva retail prices for the product are:
250mg tablets x 60 £23.76
500mg tablets x 60 £41.84
750mg tablets x 60 £71.28
1000mg tablets x 60 £80.88
Kim Innes, Commercial Director at Teva UK Limited said "We are delighted to be bringing a generic version of this product to the UK market, and at the same time further broaden our portfolio, which is the widest of any UK generics supplier."
To find out more about Teva UK Limited, visit http://www.tevauk.com.
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.
For media enquiries, contact the Teva UK Limited Communications team on +44(0)1977-628500, or email firstname.lastname@example.org.
SOURCE Teva UK Ltd